Welcome to our dedicated page for NEIGHBORHOOD INTELLIGENCE SEC filings (Ticker: BBBY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NEIGHBORHOOD INTELLIGENCE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NEIGHBORHOOD INTELLIGENCE's regulatory disclosures and financial reporting.
Bed Bath & Beyond reports results of its 2026 annual meeting. Stockholders approved a Charter amendment doubling authorized common shares from 100,000,000 to 200,000,000, giving the company more flexibility to issue stock in the future.
They also approved an amendment and restatement of the 2005 Equity Incentive Plan, adding 4,291,000 newly authorized shares for employee equity awards, plus additional shares through updated recycling provisions. All director nominees were elected, KPMG LLP was ratified as auditor for 2026, executive compensation received advisory approval, and an adjournment proposal passed but was not used. The meeting had a quorum with 49,326,700 of 69,342,333 eligible shares represented.
Bed Bath & Beyond’s former Chief Accounting Officer Leah R. Putnam reported multiple equity compensation events in the company’s common stock. On May 14, 2026, she exercised performance shares and restricted stock units into a total of 75,013 shares of common stock, while 18,268 shares were disposed of at $4.69 per share to cover tax liabilities. She also received a grant of 1,068 restricted stock units, which were approved by shareholders on May 14, 2026. Footnotes state that several restricted stock units and performance shares had their vesting accelerated in connection with her departure from the company, with vested shares to be delivered promptly after vesting.
Bed Bath & Beyond director Barclay Corbus reported several equity compensation moves. On May 15, 2026, he exercised 26,873 restricted stock units into common shares, bringing his direct common stock holdings to 105,047 shares.
He also received a new grant of 35,181 restricted stock units on May 14, 2026, which will vest at the close of business on May 14, 2027. In addition, he holds 7,816 common stock warrants originally issued on October 7, 2025, each allowing purchase of one common share at an exercise price of $15.50 per warrant through October 7, 2026.
Bed Bath & Beyond director William Benjamin Nettles Jr. reported compensation-related equity transactions, with no open-market buying or selling. On May 15, 2026, restricted stock units covering 26,873 shares of common stock vested and were delivered, increasing his direct common stock holdings to 49,747 shares.
On May 14, 2026, he received a new grant of 35,181 restricted stock units, each representing a contingent right to one share of common stock that vests at the close of business on May 14, 2027. The filing also notes 2,286 common stock warrants originally issued on October 7, 2025 as a pro‑rata distribution to all common shareholders, each with a $15.50 exercise price.
Bed Bath & Beyond director Robert Jacob Shapiro increased his equity stake through compensation-related stock transactions. On May 15, 2026, 26,873 restricted stock units vested and were converted into the same number of common shares at no cost, bringing his direct common stock holdings to 67,107 shares.
On May 14, 2026, he received a new award of 35,181 restricted stock units, each representing a right to one future common share that vests on May 14, 2027. He also holds 4,022 common stock warrants, each allowing the purchase of one share at an exercise price of $15.50 per share, originally distributed pro rata to all common stockholders in October 2025.
Bed Bath & Beyond director Joanna M. Burkey reported compensation-related equity activity. On May 15, 2026, 26,873 restricted stock units vested and were delivered as common shares, bringing her directly held common stock to 42,417 shares. The day before, she received a new grant of 35,181 restricted stock units that vest on May 14, 2027. She also holds 1,554 common stock warrants, each exercisable for one share at an exercise price of $15.50, from a pro-rata distribution originally issued on October 7, 2025.
Bed Bath & Beyond director Debra Golding Perelman reported equity compensation activity, acquiring shares through RSU vesting and receiving new awards. On May 15, 2026, 26,873 restricted stock units converted into the same number of common shares at a price of $0.00, increasing her direct common stock holdings to 32,174 shares.
On May 14, 2026, she received a grant of 35,181 restricted stock units, each representing a contingent right to one common share that vests at the close of business on May 14, 2027. She also holds 530 common stock warrants that were originally issued on October 7, 2025 in a pro-rata distribution to all common shareholders, each exercisable for one common share at an exercise price of $15.50 per warrant until October 7, 2026.
Bed Bath & Beyond director Joseph J. Tabacco Jr. reported compensation-related equity activity. On May 15, 2026, restricted stock units covering 26,873 shares of common stock vested and were converted into the same number of common shares, increasing his directly held stock.
On May 14, 2026, he also received a new grant of 35,181 restricted stock units, each representing a contingent right to one share of common stock that will vest on May 14, 2027. After these transactions, he holds 38,379 common shares directly, plus 167,209 common shares indirectly held by the Joseph Tabacco and Peggy Schmidt Revocable Trust, along with 35,181 RSUs from the new grant.
LEMONIS MARCUS reported acquisition or exercise transactions in this Form 4 filing.
Bed Bath & Beyond, Inc. executive chairman and CEO Marcus Lemonis received a grant of 1,500,000 restricted stock units, each representing a contingent right to one share of common stock. The grant was approved by shareholders on May 14, 2026, after being originally granted on March 11, 2026.
The restricted stock units vest in four equal installments at the close of business on January 1, 2027, January 1, 2028, January 1, 2029, and January 1, 2030, with vested shares delivered promptly after each vesting date. Following this transaction, Lemonis is shown as beneficially owning 1,500,000 restricted stock units from this grant.
Dubois Lisa Foley reported acquisition or exercise transactions in this Form 4 filing.
Bed Bath & Beyond, Inc. Chief Operating Officer Lisa Foley Dubois received a grant of 227,273 restricted stock units, each representing one share of common stock. The RSUs were granted on April 2, 2026, subject to shareholder approval, which was obtained on May 14, 2026.
The award vests in four equal installments at the close of business on April 2, 2027, April 2, 2028, April 2, 2029, and April 2, 2030, with shares delivered promptly after each vesting date. Following this grant, she beneficially owns 227,273 RSUs from this award.